Our Bureau, New Delhi Thursday, April 3, 2025, 08:00 Hrs [IST] ...

Japanese drugmaker Chugai (TYO: 4519) has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) ...

Chugai Pharma’s Evrysdi tablets 5mg receives Japanese approval to treat spinal muscular atrophy: Saturday, March 29, 2025, 11:00 Hrs [IST] Chugai Pharmaceutical Co., Ltd. announ ...

Roche is hoping to undercut hugely expensive rivals after the FDA approved its oral spinal muscular atrophy (SMA) drug Evrysdi (risdiplam). Evrysdi is the third treatment approved for SMA ...

Zolgensma will compete against another highly expensive drug - Biogen's Spinraza (nusinersen), while Roche is also developing a potential rival called risdiplam that is slated for a European ...

A new tablet formulation of SMA treatment Evrysdi (risdiplam) may give patients more "freedom and independence," a Genentech ...

The Delhi High Court ruled on Friday that restaurants and hotels cannot impose mandatory service charges on food bills, stating that such a practice amounts to unfair trade. The court upheld the ...

The Ministry of Law and Justice on Friday, March 28, notified the transfer of Justice Yashwant Varma of the Delhi High Court to his parent Allahabad High Court amid row over alleged discovery of cash ...

Natco Pharma Ltd., incorporated in the year 1981, is a Mid Cap company (having a market cap of Rs 14,417.45 Crore) operating in Pharmaceuticals sector. Natco Pharma Ltd. key Products/Revenue Segments ...

31 March 2025 US pharma major Eli Lilly has unveiled new Phase II data showing that its RNA-based therapy lepodisiran produced significant and lasting reductions in levels of lipoprotein(a), a known ...